I frankly don't see a whole lot of difference unless the shelf is mis-used or mgmt gets off track and starts harvesting $ for themselves. Very low chance of either IMO.
That said, I do think an offering of some sort could be in the cards.
The market is risky and there is even more risk in no revenue biotechs. CTIX has several things mitigating those risks, and those have been hashed and re-hashed on the board many times.
Good enough for me! I expected a shelf and was both relieved and nervous about it when it was announced. Relieved because $ are needed in the near future. Nervous because our little gem is entering a new phase. CTIX is entering late stage trials and it gets expensive...and the risks are different.
Market Data 
Markets 
AI
